Gilead Sciences (GILD) has signed a definitive purchase agreement to acquire Repare Therapeutics' (RPTX) polymerase theta ATPase inhibitor RP-3467 for up to $30 million, Repare said Wednesday.

Under the terms of the agreement, Repare said it will receive a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities.

RP-3467 is being evaluated in a phase 1 trial to evaluate its safety, pharmacokinetics, pharmacodynamics and preliminary activity alone or in combination with olaparib in adults with certain kinds of cancer.

Last month, Repare said it was being acquired by XenoTherapeutics and Xeno Acquisition. It added that the estimated closing net cash amount increased due to the upfront payment from Gilead.

As a result, each Repare shareholder is now expected to get a cash payment of around $2.20 per share upon closing of the Xeno transaction.